Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, gives an overview of the antibody treatment landscape for multiple myeloma, highlighting the approval of isatuximab and belantamab mafodotin and the future role of bispecific antibodies. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.